Indications for Cardiac Resynchronization Therapy (CRT) and Implantable Cardioverter-Defibrillator (ICD)
ICD Indications
ICD therapy is indicated for survivors of cardiac arrest after excluding reversible causes, and for primary prevention in patients with LVEF ≤35% who have ischemic cardiomyopathy (>40 days post-MI) or nonischemic cardiomyopathy with NYHA class II-III symptoms on guideline-directed medical therapy (GDMT), with expected survival >1 year with good functional capacity. 1
Secondary Prevention (Class I)
- Cardiac arrest survivors due to ventricular fibrillation (VF) or ventricular tachycardia (VT) after excluding reversible causes 1
- Sustained VT with structural heart disease 1
- Unexplained syncope with inducible sustained VT or VF on electrophysiologic study in patients with structural heart disease 1
Primary Prevention (Class I)
- Ischemic cardiomyopathy: LVEF ≤35%, >40 days post-MI, NYHA class II-III on GDMT 1
- Nonischemic cardiomyopathy: LVEF ≤35%, NYHA class II-III on GDMT 1
- Prior MI with LVEF ≤30% regardless of NYHA class, >40 days post-MI on GDMT 1
Special Populations (Class IIa-IIb)
- Genetic arrhythmogenic cardiomyopathy with high-risk features and LVEF ≤45% (Class IIa) 1
- Long-QT syndrome with risk factors for sudden cardiac death (Class IIb) 1
- Hypertrophic cardiomyopathy with major risk factors for sudden death (Class IIb) 1
- Nonischemic cardiomyopathy with NYHA class I and LVEF ≤35% (Class IIb) 1
Absolute Contraindications (Class III)
- Life expectancy <1 year with acceptable functional status, even if meeting other criteria 1
- Incessant VT or VF 1
- NYHA class IV drug-refractory heart failure not candidates for transplant or CRT-D 1
- Ventricular arrhythmias due to completely reversible causes (electrolyte imbalance, drugs, trauma) 1
- Significant psychiatric illness precluding systematic follow-up 1
CRT Indications
CRT is indicated for patients with LVEF ≤35% on GDMT, sinus rhythm, LBBB morphology with QRS ≥150 ms, and NYHA class II-IV symptoms to reduce mortality, hospitalizations, and improve symptoms and quality of life. 1, 2
Class I Indications (Strongest Evidence)
Sinus Rhythm with LBBB
Patients Requiring Ventricular Pacing
- Anticipated >40% ventricular pacing: LVEF ≤35% on GDMT undergoing new or replacement device implantation 1
- AV block or complete heart block: LVEF 36-50% (Class IIa for this LVEF range) 1
Class IIa Indications (Reasonable)
Sinus Rhythm with LBBB
- QRS 120-149 ms: LVEF ≤35%, NYHA class II, III, or ambulatory IV, LBBB morphology on GDMT 1
- Evidence is less robust than for QRS ≥150 ms but still demonstrates benefit 1
Atrial Fibrillation
- Permanent AF: LVEF ≤35%, NYHA class III-IV on GDMT, if AV nodal ablation or pharmacologic rate control achieves near 100% (≥95%) ventricular pacing with CRT 1
Class IIb Indications (May Be Considered)
Highly Selected Patients
- NYHA class I: LVEF ≤30%, ischemic etiology, sinus rhythm, LBBB with QRS ≥150 ms on GDMT 1, 2
- Non-LBBB with QRS 120-149 ms: NYHA class III or ambulatory IV on GDMT 1
- Non-LBBB with QRS ≥150 ms: NYHA class II on GDMT 1
Class III (Not Recommended)
- QRS <120 ms: No benefit demonstrated regardless of echocardiographic dyssynchrony 1, 2
- NYHA class I-II with non-LBBB and QRS <150 ms: No benefit shown 1
- Life expectancy <1 year with good functional capacity due to comorbidities or frailty 1, 2
CRT-D versus CRT-P Decision Algorithm
Choose CRT-D When:
- NYHA class I-II patients meeting CRT criteria, as survival benefit demonstrated only in CRT-D trials 2
- Conventional ICD indication exists (ischemic cardiomyopathy, prior cardiac arrest, sustained VT) 1
- Younger patients with ischemic cardiomyopathy and reasonable life expectancy 2
Choose CRT-P When:
- NYHA class III-IV patients where ICD unlikely to provide meaningful survival advantage 2
- Advanced age with significant comorbidities 2
- Nonischemic cardiomyopathy without arrhythmia history 2
- Patient preference against defibrillator shocks 2
Critical Implementation Points
Pre-Implantation Requirements
- Optimize GDMT first: Maximize ACE-inhibitors/ARBs, beta-blockers, and mineralocorticoid receptor antagonists for ≥3 months (or ≥40 days post-MI) 2
- Reassess LVEF after GDMT optimization, as some patients improve and no longer meet criteria 1
- Avoid implantation during acute decompensation: Stabilize patients and reassess in outpatient setting 2
QRS Morphology Hierarchy
- LBBB confers strongest benefit: Meta-analysis shows significant reduction in adverse events (RR 0.64) with LBBB versus no benefit with non-LBBB (RR 0.97) 1
- Non-LBBB requires QRS ≥150 ms: For non-LBBB patterns, only QRS ≥150 ms shows potential benefit 1
- Right bundle branch block: Particularly poor outcomes, with RBBB predicting non-favorable response 1
Atrial Fibrillation Management
- Target ≥95% biventricular pacing: Pharmacologic rate control alone often insufficient 1
- AV junction ablation mandatory if <90-95% biventricular capture achieved with medications 1
- Consider pulmonary vein isolation if indicated for AF management 1
Common Pitfalls to Avoid
- Do not implant CRT in QRS <120 ms even with echocardiographic dyssynchrony—this may cause harm 1, 3
- Do not use CRT-D in patients with <1 year life expectancy—competing mortality risks negate benefit 1, 2
- Do not accept suboptimal biventricular pacing in AF—ensure near-complete capture or perform AV junction ablation 1
- Do not implant during acute decompensation—LVEF may improve with medical therapy alone 2